Works by Kemppainen, Jukka


Results: 69
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI.

    Published in:
    Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-66255-8
    By:
    • Movahedi, Parisa;
    • Merisaari, Harri;
    • Perez, Ileana Montoya;
    • Taimen, Pekka;
    • Kemppainen, Jukka;
    • Kuisma, Anna;
    • Eskola, Olli;
    • Teuho, Jarmo;
    • Saunavaara, Jani;
    • Pesola, Marko;
    • Kähkönen, Esa;
    • Ettala, Otto;
    • Liimatainen, Timo;
    • Pahikkala, Tapio;
    • Boström, Peter;
    • Aronen, Hannu;
    • Minn, Heikki;
    • Jambor, Ivan
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26

    Response to Letter on use of functional imaging by <sup>11</sup>C-metomidate PET for primary aldosteronism subtyping.

    Published in:
    European Journal of Endocrinology, 2021, v. 184, n. 3, p. L11, doi. 10.1530/EJE-21-0048
    By:
    • Soinio, Minna;
    • Luukkonen, Anna-Kaarina;
    • Seppänen, Marko;
    • Kemppainen, Jukka;
    • Seppänen, Janne;
    • Pienimäki, Juha-Pekka;
    • Leijon, Helena;
    • Vesterinen, Tiina;
    • Arola, Johanna;
    • Lantto, Eila;
    • Helin, Semi;
    • Tikkanen, Ilkka;
    • Metso, Saara;
    • Mirtti, Tuomas;
    • Heiskanen, Ilkka;
    • Norvio, Leena;
    • Tiikkainen, Mirja;
    • Tikkanen, Tuula;
    • Sane, Timo;
    • Välimäki, Matti
    Publication type:
    Article
    27

    Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism.

    Published in:
    European Journal of Endocrinology, 2020, v. 183, n. 6, p. 539, doi. 10.1530/EJE-20-0532
    By:
    • Soinio, Minna;
    • Luukkonen, Anna-Kaarina;
    • Seppänen, Marko;
    • Kemppainen, Jukka;
    • Seppänen, Janne;
    • Pienimäki, Juha-Pekka;
    • Leijon, Helena;
    • Vesterinen, Tiina;
    • Arola, Johanna;
    • Lantto, Eila;
    • Helin, Semi;
    • Tikkanen, Ilkka;
    • Metso, Saara;
    • Mirtti, Tuomas;
    • Heiskanen, Ilkka;
    • Norvio, Leena;
    • Tiikkainen, Mirja;
    • Tikkanen, Tuula;
    • Sane, Timo;
    • Välimäki, Matti
    Publication type:
    Article
    28

    Value of <sup>68</sup>Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [<sup>18</sup>F]fluoromethylcholine PET-CT and multiparametric MRI—a phase I/II study.

    Published in:
    European Radiology, 2023, v. 33, n. 1, p. 472, doi. 10.1007/s00330-022-08982-2
    By:
    • Beheshti, Mohsen;
    • Taimen, Pekka;
    • Kemppainen, Jukka;
    • Jambor, Ivan;
    • Müller, Andre;
    • Loidl, Wolfgang;
    • Kähkönen, Esa;
    • Käkelä, Meeri;
    • Berndt, Mathias;
    • Stephens, Andrew W.;
    • Minn, Heikki;
    • Langsteger, Werner
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35
    36
    37

    Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 9, p. 2951, doi. 10.1007/s00259-021-05296-1
    By:
    • Malaspina, Simona;
    • Anttinen, Mikael;
    • Taimen, Pekka;
    • Jambor, Ivan;
    • Sandell, Minna;
    • Rinta-Kiikka, Irina;
    • Kajander, Sami;
    • Schildt, Jukka;
    • Saukko, Ekaterina;
    • Noponen, Tommi;
    • Saunavaara, Jani;
    • Dean, Peter B.;
    • Sequeiros, Roberto Blanco;
    • Aronen, Hannu J.;
    • Kemppainen, Jukka;
    • Seppänen, Marko;
    • Boström, Peter J.;
    • Ettala, Otto
    Publication type:
    Article
    38
    39
    40

    Prospective evaluation of F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2018, v. 45, n. 3, p. 355, doi. 10.1007/s00259-017-3875-1
    By:
    • Jambor, Ivan;
    • Kuisma, Anna;
    • Kähkönen, Esa;
    • Kemppainen, Jukka;
    • Merisaari, Harri;
    • Eskola, Olli;
    • Teuho, Jarmo;
    • Perez, Ileana Montoya;
    • Pesola, Marko;
    • Aronen, Hannu J.;
    • Boström, Peter J.;
    • Taimen, Pekka;
    • Minn, Heikki
    Publication type:
    Article
    41
    42
    43
    44

    Correlation between <sup>18</sup>F-1-amino-3-fluorocyclobutane-1-carboxylic acid (<sup>18</sup>F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.

    Published in:
    EJNMMI Research, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1186/s13550-019-0518-5
    By:
    • Saarinen, Irena;
    • Jambor, Ivan;
    • Kim, Mai;
    • Kuisma, Anna;
    • Kemppainen, Jukka;
    • Merisaari, Harri;
    • Eskola, Olli;
    • Koskenniemi, Anna-Riina;
    • Perez, Ileana Montoya;
    • Boström, Peter;
    • Taimen, Pekka;
    • Minn, Heikki
    Publication type:
    Article
    45
    46
    47
    48
    49
    50

    Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.

    Published in:
    Acta Oncologica, 2016, v. 55, n. 1, p. 59, doi. 10.3109/0284186X.2015.1027411
    By:
    • Jambor, Ivan;
    • Aronen, Hannu J.;
    • Kuisma, Anna;
    • Ramadan, Susan;
    • Huovinen, Riikka;
    • Minn, Heikki;
    • Sandell, Minna;
    • Auren, Joakim;
    • Saunavaara, Jani;
    • Kajander, Sami;
    • Kemppainen, Jukka;
    • Merisaari, Harri;
    • Seppänen, Marko;
    • Kauppila, Esa;
    • Noponen, Tommi
    Publication type:
    Article